Encompass Health (NYSE:EHC) Given New $118.00 Price Target at Barclays

Encompass Health (NYSE:EHC) had its price target raised by Barclays from $116.00 to $118.00 in a research report sent to investors on Friday,Benzinga reports. Barclays currently has an overweight rating on the stock.

Several other research analysts also recently weighed in on the stock. Truist Financial restated a “buy” rating and issued a $116.00 target price (up from $108.00) on shares of Encompass Health in a research note on Wednesday, October 30th. Royal Bank of Canada raised their target price on Encompass Health from $105.00 to $110.00 and gave the company an “outperform” rating in a research note on Wednesday, October 30th. William Blair reiterated an “outperform” rating on shares of Encompass Health in a research note on Friday. Finally, KeyCorp increased their target price on Encompass Health from $115.00 to $117.00 and gave the company an “overweight” rating in a research note on Tuesday, October 29th. One research analyst has rated the stock with a hold rating, nine have issued a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Buy” and an average target price of $107.33.

Encompass Health Price Performance

EHC stock opened at $99.86 on Friday. Encompass Health has a 52-week low of $72.37 and a 52-week high of $104.55. The company has a quick ratio of 1.04, a current ratio of 1.04 and a debt-to-equity ratio of 0.88. The stock’s fifty day simple moving average is $96.28 and its 200-day simple moving average is $95.19. The stock has a market capitalization of $10.06 billion, a price-to-earnings ratio of 24.12, a price-to-earnings-growth ratio of 1.18 and a beta of 0.90.

Encompass Health (NYSE:EHC) last released its quarterly earnings data on Thursday, February 6th. The company reported $1.17 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.05 by $0.12. Encompass Health had a net margin of 8.10% and a return on equity of 17.60%. Equities research analysts expect that Encompass Health will post 4.29 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. CIBC Asset Management Inc grew its position in Encompass Health by 3.5% in the 3rd quarter. CIBC Asset Management Inc now owns 2,957 shares of the company’s stock valued at $286,000 after buying an additional 100 shares in the last quarter. Miracle Mile Advisors LLC grew its position in Encompass Health by 3.0% in the fourth quarter. Miracle Mile Advisors LLC now owns 3,835 shares of the company’s stock worth $354,000 after buying an additional 112 shares during the last quarter. US Bancorp DE raised its position in shares of Encompass Health by 9.6% during the fourth quarter. US Bancorp DE now owns 1,380 shares of the company’s stock worth $127,000 after purchasing an additional 121 shares during the period. MassMutual Private Wealth & Trust FSB boosted its holdings in shares of Encompass Health by 87.8% in the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 293 shares of the company’s stock worth $27,000 after buying an additional 137 shares during the period. Finally, V Square Quantitative Management LLC grew its position in Encompass Health by 53.0% during the 3rd quarter. V Square Quantitative Management LLC now owns 404 shares of the company’s stock worth $39,000 after purchasing an additional 140 shares in the last quarter. Institutional investors own 97.25% of the company’s stock.

Encompass Health Company Profile

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.